Elevated Body Mass Index and Use of Coronary Revascularization after Cardiac Catheterization - 12/08/11
Abstract |
Background |
Obese persons suffer discrimination in society that may extend to health care use. We investigated whether overweight and obese patients are as likely to undergo coronary reperfusion or revascularization as patients of normal body weight.
Methods |
Detailed clinical data were collected for an inception cohort of patients from Alberta, Canada, who underwent cardiac catheterization between April 2001 and March 2004. The patients' likelihood of receiving any revascularization, percutaneous coronary intervention, or coronary artery bypass graft surgery in the year after cardiac catheterization was examined on the basis of body mass index (BMI) grouping. Use of revascularization was examined separately for patients with high- and low-risk coronary disease.
Results |
Of 27,460 patients who had BMI data recorded, 24% were of normal weight, 42% were overweight, and 35% were obese. Although overweight and obese patients were more likely to have percutaneous coronary intervention (adjusted hazard ratio [HR]=1.07, 95% confidence interval [CI], 1.01-1.12 and HR 1.08, 95% CI, 1.01-1.13, respectively), obese patients (BMI>30) were less likely to receive coronary artery bypass graft surgery (adjusted HR=0.93, 95% CI, 0.87-1.00). This was primarily because of less use of coronary artery bypass graft surgery for the most obese patients (obesity class III) with low-risk coronary anatomy (adjusted HR=0.61, 95% CI, 0.36-1.02).
Conclusion |
The pattern of use of revascularization procedures after cardiac catheterization differs somewhat across BMI subgroups. These differences might be clinically appropriate, but they warrant further exploration.
Le texte complet de cet article est disponible en PDF.Keywords : Access, Coronary revascularization, Obesity
Plan
Funding: The Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease was initially funded with a grant from the W. Garfield Weston Foundation. The ongoing operation of this project has been made possible by operating grants from the Heart and Stroke Foundation of Alberta, Northwest Territories, and Nunavut, and the Canadian Institutes of Health Research, as well as support from the Canadian Cardiovascular Outcomes Research Team, a Canadian Institutes of Health Research-funded team grant initiative. The initiative also has received contributions from Alberta Health and Wellness, Merck Frosst Canada Inc, Monsanto Canada Inc-Searle, Eli Lilly Canada Inc, Guidant Corporation, Boston Scientific Ltd, Hoffmann-La Roche Ltd, and Johnson & Johnson Inc—Cordis. Dr King holds a Health Scholar Award from the Alberta Heritage Foundation for Medical Research. Dr Knudtson receives partial support from the Libin Trust Fund. Dr Ghali is supported by a Government of Canada Research Chair in Health Services Research and by a Senior Health Scholar Award from the Alberta Heritage Foundation for Medical Research. |
|
Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this article. |
|
Authorship: All authors had access to the data and played a role in writing this article. |
Vol 122 - N° 3
P. 273-280 - mars 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?